Chiropractors in Southport, CT Accepting Medicare
6 Chiropractors found. Showing 1 - 6
 Connie Seo, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2600 Post Rd, Suite L2, Southport, CT 06890 Phone: 203-254-9432 Fax: 203-254-9462 |
 Sabita Holistic Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 3519 Post Rd, Southport, CT 06890 Phone: 203-254-2633 |
Dr. Breanna Lyn Razdan, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2600 Post Rd, Southport, CT 06890 Phone: 203-254-9432 Fax: 203-333-2700 |
Serenity Chiropractic And Wellness Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2600 Post Rd, Suite L2, Southport, CT 06890 Phone: 203-254-9432 Fax: 203-254-9462 |
 Dr. Robert W Kipp Jr., D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2600 Post Rd, Suite L2, Southport, CT 06890 Phone: 203-333-2700 Fax: 203-333-2703 |
Pro-health Chiropractic, P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 2600 Post Rd, Suite L2, Southport, CT 06890 Phone: 203-333-2700 Fax: 203-333-2703 |
News Archive
Micronics receives FDA marketing clearance for ABORhCard
Micronics, Inc., a medical device development company, today announced that the U.S. Food and Drug Administration has granted the company 510(k) clearance to market its ABORhCard, a qualitative in vitro test that provides a simultaneous determination of an individual's ABO blood group and Rh factor status. It is not for use for blood bank processing of blood products, for determining RHD status for the purpose of administration of Rh immunoglobulin, or for screening purposes prior to transfusion.
Occurrence and persistence of SARS-CoV-2 in wastewater
Researchers review the utilities of wastewater epidemiology in assessing the prevalence of SARS-CoV-2 in a given community as well as the risks of wastewater viral transmission.
Kiadis Pharma receives two orphan drug designations for Reviroc
Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL).
AbstralTM continues strong growth of over 40% in first-quarter 2010
Orexo AB today confirms that its partner, ProStrakan Group plc has announced that AbstralTM continues to show strong sales development in 2010.
Case for smoke-free work and public places
An economic case for smoke-free work and public places is being made today in an independent report from the Chief Medical Officer.
› Verified 8 days ago
Physical Therapists
Optometrists
Chiropractors
Audiologists
Speech-Language Pathologists